Back to top
more

Akero Therapeutics (AKRO)

(Delayed Data from NSDQ)

$26.41 USD

26.41
446,533

+0.06 (0.23%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $26.41 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

by Zacks Equity Research

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

by Zacks Equity Research

Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss

by Zacks Equity Research

Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.

Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.

Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up

by Zacks Equity Research

Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.

Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues

by Zacks Equity Research

Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.

Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y

by Zacks Equity Research

Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.

Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.

Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year

by Zacks Equity Research

Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Akero Therapeutics (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

by Zacks Equity Research

Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

by Zacks Equity Research

Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

by Zacks Equity Research

Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

by Zacks Equity Research

Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 58.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus

by Zacks Equity Research

Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.

Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

by Zacks Equity Research

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.